{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:27:24Z","timestamp":1790332044275,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":3699,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s13311-013-0193-6","type":"journal-article","created":{"date-parts":[[2013,5,6]],"date-time":"2013-05-06T09:56:15Z","timestamp":1367834175000},"page":"447-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Intrabodies as Neuroprotective Therapeutics"],"prefix":"10.1016","volume":"10","author":[{"given":"Anne","family":"Messer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhada N.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0193-6_bib1","first-page":"2638","article-title":"A new means of inducibly inactivating a cellular protein","volume":"8","author":"Carlson","year":"1988","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-013-0193-6_bib2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.biocel.2008.07.001","article-title":"Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription","volume":"41","author":"Mukhtar","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1007\/s13311-013-0193-6_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2004.04.062","article-title":"Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity","volume":"340","author":"Aires da Silva","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/14712598.7.5.677","article-title":"Intrabody strategies for the treatment of human papillomavirus-associated disease","volume":"7","author":"Doorbar","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1007\/s13311-013-0193-6_bib5","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1089\/hum.1998.9.11-1627","article-title":"Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy","volume":"9","author":"Marasco","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1007\/s13311-013-0193-6_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-3-540-73259-4_15","article-title":"Intracellular antibodies (intrabodies) and their therapeutic potential","author":"Lo","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"10.1007\/s13311-013-0193-6_bib7","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1038\/sj.emboj.7601744","article-title":"Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS","volume":"26","author":"Tanaka","year":"2007","journal-title":"EMBO J"},{"key":"10.1007\/s13311-013-0193-6_bib8","first-page":"397","article-title":"Conditional inactivation of HIF-1 using intrabodies","volume":"30","author":"Groot","year":"2008","journal-title":"Cell Oncol"},{"key":"10.1007\/s13311-013-0193-6_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00063030-200620060-00002","article-title":"The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases","volume":"20","author":"Messer","year":"2006","journal-title":"BioDrugs"},{"key":"10.1007\/s13311-013-0193-6_bib10","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0193-6_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molmed.2008.07.004","article-title":"The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases","volume":"14","author":"Cardinale","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1007\/s13311-013-0193-6_bib12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/14712590903176387","article-title":"Developing intrabodies for the therapeutic suppression of neurodegenerative pathology","volume":"9","author":"Messer","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1007\/s13311-013-0193-6_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbadis.2008.09.001","article-title":"Intrabody and Parkinson's disease","volume":"1792","author":"Zhou","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1007\/s13311-013-0193-6_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0065-3233(08)60493-3","article-title":"Antibody binding sites","volume":"49","author":"Huston","year":"1996","journal-title":"Adv Protein Chem"},{"key":"10.1007\/s13311-013-0193-6_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","article-title":"Camelid immunoglobulins and nanobody technology","volume":"128","author":"Muyldermans","year":"2009","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1007\/s13311-013-0193-6_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1007\/s13311-013-0193-6_bib17","first-page":"327","article-title":"van Bergen en Henegouwen PM. Nanobodies in therapeutic applications","volume":"9","author":"Roovers","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"10.1007\/s13311-013-0193-6_bib18","doi-asserted-by":"crossref","first-page":"19232","DOI":"10.1073\/pnas.0703793104","article-title":"Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils","volume":"104","author":"Habicht","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/hmg\/ddp101","article-title":"Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo","volume":"18","author":"Chartier","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pneurobio.2011.11.004","article-title":"Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins","volume":"97","author":"Butler","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s13311-013-0193-6_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzq022","article-title":"Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm","volume":"23","author":"Kvam","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"10.1007\/s13311-013-0193-6_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-013-0193-6_bib23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0193-6_bib24","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0006-8993(99)01451-1","article-title":"Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice","volume":"835","author":"Manley","year":"1999","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0193-6_bib26","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","article-title":"Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis","volume":"12","author":"Kennedy","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/exnr.2000.7551","article-title":"ST14A cells have properties of a medium-size spiny neuron","volume":"167","author":"Ehrlich","year":"2001","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0193-6_bib28","doi-asserted-by":"crossref","first-page":"e5727","DOI":"10.1371\/journal.pone.0005727","article-title":"Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity","volume":"4","author":"Kvam","year":"2009","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0193-6_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2004.11.003","article-title":"A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease","volume":"19","author":"Miller","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0193-6_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","article-title":"Huntington's disease: can mice lead the way to treatment?","volume":"69","author":"Crook","year":"2011","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0193-6_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0193-6_bib32","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0193-6_bib33","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J Comp Neurol"},{"key":"10.1007\/s13311-013-0193-6_bib35","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1074\/jbc.M111.305417","article-title":"Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay","volume":"287","author":"Gupta","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0193-6_bib36","series-title":"Gene therapy of the central nervous system: from bench to bedside","first-page":"133","article-title":"Gene therapy for CNS diseases using Intrabodies","author":"Miller","year":"2006"},{"key":"10.1007\/s13311-013-0193-6_bib37","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","article-title":"Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity","volume":"99","author":"Khoshnan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jmb.2011.09.014","article-title":"The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains","volume":"413","author":"Robertson","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jmb.2012.01.030","article-title":"Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence","volume":"421","author":"Wetzel","year":"2012","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib40","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","article-title":"Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease","volume":"98","author":"Lecerf","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molbrainres.2003.11.011","article-title":"A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease","volume":"121","author":"Murphy","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1007\/s13311-013-0193-6_bib42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0193-6_bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1092194","article-title":"SUMO modification of Huntingtin and Huntington's disease pathology","volume":"304","author":"Steffan","year":"2004","journal-title":"Science"},{"key":"10.1007\/s13311-013-0193-6_bib44","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","article-title":"Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies","volume":"102","author":"Wolfgang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib45","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1096\/fj.07-099689","article-title":"Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease","volume":"22","author":"McLear","year":"2008","journal-title":"FASEB J"},{"key":"10.1007\/s13311-013-0193-6_bib46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nbd.2010.04.007","article-title":"Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease","volume":"40","author":"Bortvedt","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0193-6_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","article-title":"Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington's disease","volume":"41","author":"Hathorn","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0193-6_bib48","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-013-0193-6_bib49","doi-asserted-by":"crossref","first-page":"17616","DOI":"10.1073\/pnas.0408134101","article-title":"Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody","volume":"101","author":"Colby","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib50","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmb.2004.07.054","article-title":"Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display","volume":"342","author":"Colby","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib51","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0193-6_bib52","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0193-6_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jmb.2011.09.034","article-title":"A Disulfide-Free Single-Domain V(L) Intrabody with Blocking activity towards huntingtin reveals a novel mode of epitope recognition","volume":"414","author":"Schiefner","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib54","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0193-6_bib55","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1074\/jbc.M109.013193","article-title":"Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity","volume":"284","author":"Aiken","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0193-6_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/hmg\/ddl440","article-title":"The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis","volume":"16","author":"Rockabrand","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1523\/JNEUROSCI.1409-03.2004","article-title":"Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction","volume":"24","author":"Qin","year":"2004","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0193-6_bib58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0361-9230(01)00599-8","article-title":"New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins","volume":"56","author":"Ko","year":"2001","journal-title":"Brain Res Bull"},{"key":"10.1007\/s13311-013-0193-6_bib59","doi-asserted-by":"crossref","first-page":"e16676","DOI":"10.1371\/journal.pone.0016676","article-title":"Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1","volume":"6","author":"Southwell","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0193-6_bib60","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","article-title":"Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin","volume":"181","author":"Wang","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1007\/s13311-013-0193-6_bib61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","article-title":"Parkinson's disease: genetics and pathogenesis","volume":"6","author":"Shulman","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1007\/s13311-013-0193-6_bib62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0193-6_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1750-1326-4-9","article-title":"alpha-Synuclein and neuronal cell death","volume":"4","author":"Cookson","year":"2009","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-013-0193-6_bib64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","article-title":"Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"377","author":"Nalls","year":"2011","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0193-6_bib65","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/NDT.S2013","article-title":"Potential cellular and regenerative approaches for the treatment of Parkinson's disease","volume":"4","author":"Lane","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1007\/s13311-013-0193-6_bib66","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.296.6.661","article-title":"Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease","volume":"296","author":"Maraganore","year":"2006","journal-title":"JAMA"},{"key":"10.1007\/s13311-013-0193-6_bib67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1750-1326-6-6","article-title":"Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?","volume":"6","author":"Greggio","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-013-0193-6_bib68","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1073\/pnas.1004676107","article-title":"Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice","volume":"107","author":"Tong","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0193-6_bib70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0193-6_bib71","doi-asserted-by":"crossref","first-page":"e5515","DOI":"10.1371\/journal.pone.0005515","article-title":"Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy","volume":"4","author":"Xilouri","year":"2009","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0193-6_bib72","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12035-012-8330-5","article-title":"Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration","volume":"47","author":"Beyer","year":"2013","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-013-0193-6_bib73","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1074\/jbc.M008919200","article-title":"A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly","volume":"276","author":"Giasson","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0193-6_bib74","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jmb.2007.11.096","article-title":"An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity","volume":"377","author":"Lynch","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib75","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.0285-07.2007","article-title":"Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo","volume":"27","author":"Periquet","year":"2007","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0193-6_bib76","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2004.08.019","article-title":"A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein","volume":"10","author":"Zhou","year":"2004","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0193-6_bib77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2009.04.046","article-title":"Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells","volume":"459","author":"Yuan","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-013-0193-6_bib78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12104-009-9182-4","article-title":"(1)H, (13)C and (15)N assignments of a camelid nanobody directed against human alpha-synuclein","volume":"3","author":"Vuchelen","year":"2009","journal-title":"Biomol NMR Assign"},{"key":"10.1007\/s13311-013-0193-6_bib79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jmb.2010.07.001","article-title":"Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody","volume":"402","author":"De Genst","year":"2010","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib80","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jmb.2007.02.089","article-title":"Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity","volume":"368","author":"Emadi","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib81","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1074\/jbc.M806559200","article-title":"Detecting morphologically distinct oligomeric forms of alpha-synuclein","volume":"284","author":"Emadi","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0193-6_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2013.01.040","article-title":"Nanobodies raised against monomeric alpha-synuclein distinguish between fibrils at different maturation stages","author":"Guilliams","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(96)10031-1","article-title":"PEST sequences and regulation by proteolysis","volume":"21","author":"Rechsteiner","year":"1996","journal-title":"Trends Biochem Sci"},{"key":"10.1007\/s13311-013-0193-6_bib84","doi-asserted-by":"crossref","first-page":"e29199","DOI":"10.1371\/journal.pone.0029199","article-title":"Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments","volume":"6","author":"Butler","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0193-6_bib85","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1093\/hmg\/11.22.2689","article-title":"Aggregate formation inhibits proteasomal degradation of polyglutamine proteins","volume":"11","author":"Verhoef","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib86","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/hmg\/11.9.1107","article-title":"Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy","volume":"11","author":"Ravikumar","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib87","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/hmg\/ddq093","article-title":"Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease","volume":"19","author":"Rose","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib88","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1111\/j.1742-4658.2008.06562.x","article-title":"Huntington's disease: degradation of mutant huntingtin by autophagy","volume":"275","author":"Sarkar","year":"2008","journal-title":"FEBS J"},{"key":"10.1007\/s13311-013-0193-6_bib89","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nbt.1608","article-title":"Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein","volume":"28","author":"Bauer","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-013-0193-6_bib90","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.21696","article-title":"Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies","author":"Joshi","year":"2012","journal-title":"MAbs"},{"key":"10.1007\/s13311-013-0193-6_bib91","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/hmg\/ddr507","article-title":"alpha-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease","volume":"21","author":"Tomas-Zapico","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.febslet.2011.11.019","article-title":"alpha-Synuclein modifies huntingtin aggregation in living cells","volume":"586","author":"Herrera","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1007\/s13311-013-0193-6_bib93","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4161\/auto.19259","article-title":"alpha-Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology","volume":"8","author":"Corrochano","year":"2012","journal-title":"Autophagy"},{"key":"10.1007\/s13311-013-0193-6_bib94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/1471-2148-8-231","article-title":"Robustness promotes evolvability of thermotolerance in an RNA virus","volume":"8","author":"McBride","year":"2008","journal-title":"BMC Evol Biol"},{"key":"10.1007\/s13311-013-0193-6_bib95","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0193-6_bib96","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0193-6_bib97","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.neuron.2012.06.001","article-title":"\"Huntingtin holiday\": progress toward an antisense therapy for Huntington's disease","volume":"74","author":"Lu","year":"2012","journal-title":"Neuron."},{"key":"10.1007\/s13311-013-0193-6_bib98","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1093\/hmg\/ddr110","article-title":"Genetic therapy for the nervous system","volume":"20","author":"Bowers","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0193-6_bib99","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.nbd.2011.12.030","article-title":"Gene therapy for Huntington's disease","volume":"48","author":"Ramaswamy","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0193-6_bib100","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/hum.2010.202","article-title":"Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial","volume":"22","author":"Allay","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1007\/s13311-013-0193-6_bib101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/mt.2012.167","article-title":"Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses","volume":"21","author":"Ciesielska","year":"2013","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0193-6_bib102","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/STROKEAHA.109.572537","article-title":"Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats","volume":"41","author":"Zhan","year":"2010","journal-title":"Stroke"},{"key":"10.1007\/s13311-013-0193-6_bib103","doi-asserted-by":"crossref","first-page":"84ra43","DOI":"10.1126\/scitranslmed.3002254","article-title":"A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo","volume":"3","author":"Atwal","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0193-6_bib104","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0193-6_bib105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.brainres.2012.02.030","article-title":"RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity","volume":"1462","author":"Echeverria","year":"2012","journal-title":"Brain Res"},{"key":"10.1007\/s13311-013-0193-6_bib106","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1073\/pnas.1013343108","article-title":"Non-ATG-initiated translation directed by microsatellite expansions","volume":"108","author":"Zu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0193-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0193-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:53:08Z","timestamp":1761807188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1878747923012357"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0193-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrabodies as Neuroprotective Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0193-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}